Multi-Lab Testing of Early Preclinical Discoveries Identifies Promising Treatments
Pellegrini, P.; Rotter, S. C.; Arroyo-Araujo, M.; Carneiro, C. F. D.; Drude, N. I.; Martinez Gamboa, L.; Banito, A.; Bernhardt, N.; Boulesteix, A.-L.; Buttgereit, F.; Dempfle, A.; Duran-Hernandez, N.; Gaber, T.; Groettrup, M.; Habelt, B.; Haller, B.; Hamza, H.; Hettmer, S.; Kliesow Remes, A.; Kobold, S.; Kochan, M.; Konietschke, F.; Lehmann, L. H.; Löhning, M.; Matzen, A.; Meinhardt, M. W.; Morrison, H.; Müller, O. J.; Planz, O.; Richter, G. H. S.; Riecken, L. B.; Rosahl, S. K.; Rubarth, K.; Schmidt-Bleek, K.; Schuler, L.; Sharma, A.; Skorodumov, I.; Spanagel, R.; Teichert-von Lüttichau, I.
Show abstract
A fundamental challenge in drug development is the frequent failure of early laboratory research to translate into clinical benefit. One promising solution is to confirm findings from exploratory single-laboratory studies across multiple laboratories before clinical testing. We investigated this approach following the conduct of preclinical multi-laboratory studies across different fields of medicine. For this, we evaluated effect sizes, experimental rigor, and a set of criteria to identify determinants of confirmation success. When tested under increased rigor, only a fraction of multi-laboratory studies confirmed the initial results. The underlying effect size reduction was associated with outcome-relevant experimental differences between exploratory and confirmatory stages. In summary, multi-laboratory studies proved highly informative and served as an effective filter for promising treatments.
Matching journals
The top 4 journals account for 50% of the predicted probability mass.
Similar papers in this journal
- A Scoping Review of Artificial Intelligence Applications in Clinical Trial Risk Assessment 94%
- Exploring the Feasibility of Using Real-World Data from a Large Clinical Data Research Network to Simulate Clinical Trials of Alzheimer’s Disease 92%
- The IDentif.AI 2.0 Pandemic Readiness Platform: Rapid Prioritization of Optimized COVID-19 Combination Therapy Regimens 91%
Similar papers in this journal
- Repurposing Therapeutics for COVID-19: Rapid Prediction of Commercially available drugs through Machine Learning and Docking 93%
- Exploring scalable assessment methods for terminated trials in ClinicalTrials.gov: A cohort analysis of German and Californian trials 92%
- Significant Relaxation of SARS-CoV-2-Targeted Non-Pharmaceutical Interventions Will Result in Profound Mortality: A New York State Modelling Study 92%
Similar papers in this journal
- Multicenter preclinical studies as an innovative method to enhance translation: a systematic review of published studies 91%
- Systematic analysis of electronic health records identifies drugs reducing risk of COVID-19 hospitalization and severity 91%
- The Proportion of Randomized Controlled Trials That Inform Clinical Practice: A Longitudinal Cohort Study of Trials Registered on ClinicalTrials.gov 90%
Similar papers in this journal
- Almost significant: trends and P values in the use of phrases describing marginally significant results in 567,758 randomized controlled trials published between 1990 and 2020 90%
- Randomized clinical trial quality has improved over time but is still not good enough: an analysis of 176,620 randomized controlled trials published between 1966 and 2018 90%
- Assessment of transparency indicators across the biomedical literature: how open is open? 89%
Similar papers in this journal
- Refined Tamoxifen Administration in Mice by Encouraging Voluntary Consumption of Palatable Formulations. 88%
- Diet gel-based oral drug delivery system for controlled dosing of small molecules for microglia depletion and inducible Cre recombination in mice 88%
- GrimACE: Automated, multimodal cage-side assessment of pain and well-being in mice 87%
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.